Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eleonora Galosi has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Reasoning: A Patient With Progressive Sensory Neuropathy

    by Giuseppe Di Pietro, Pietro Falco, Eleonora Galosi, Enrico Evangelisti, Daniel Litewczuk, Gianfranco De Stefano, Giulia Di Stefano, Filippo Camerota, Caterina Leone, Andrea Truini

    A 74-year-old man presented with a 5-year history of progressive feet numbness followed by gait unsteadiness. Neurologic examination revealed absent tendon reflexes, markedly reduced vibration sens...

  • Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes

    by Pietro Falco, Alessandra Di Flaviani, Eleonora Galosi, Stefania Angotti, Gianfranco De Stefano, Giuseppe Di Pietro, Giulia Di Stefano, Luca D'ONofrio, Enrico Evangelisti, Caterina Leone, et al.

    In this cross-sectional study, we investigated the frequency of diabetic peripheral neuropathy (DPN) and DPN-related neuropathic pain (painful DPN) in 500 consecutively enrolled patients with type 2 diabetes mellitus receiving standard treatment (n = 208), sodium–glucose cotransporter-2 inhibitors (SGLT2i; n = 152), or glucagon-like peptide-1 receptor agonists (GLP-1 RAs; n = 140). DPN was assessed through neurological examination, nerve conduction study, and skin biopsy when indicated; painful DPN was diagnosed using the grading system for neuropathic pain. Neuropathy severity and pain intensity were quantified with the Toronto Clinical Neuropathy Score, Pain Numerical Rating Scale, and Neuropathic Pain Symptom Inventory. The overall frequency of DPN was 58.6%, and painful DPN occurred in 26.2% of patients. GLP-1 RA treatment was associated with a lower frequency of DPN (46.4% vs 60.6% in the standard treatment group) and painful DPN (10.1% vs 35.1% and 28.3% in the standard treatment and SGLT2i groups, respectively). After adjustment for clinical and metabolic covariates, GLP-1 RA treatment was independently associated with lower odds of DPN (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.37-0.96) and painful DPN (OR 0.32, 95% CI 0.15-0.65). Neuropathy severity and pain intensity were also lower in patients receiving GLP-1 RAs. GLP-1 RA treatment was associated with a reduced frequency and severity of both DPN and painful DPN, independent of clinical and metabolic covariates. While these findings suggest potential neuroprotective and antinociceptive effects, longitudinal studies are needed to establish causality and clarify the underlying mechanisms.


  • Open Access

    Quantitative Sensory Testing Identifies Altered Thermal and Pain Processing in Trigeminal Neuralgia

    by Gianfranco De Stefano, Daniel Litewczuk, Eleonora Galosi, Giuseppe Di Pietro, Pietro Falco, Caterina Leone, Jibril Osman‐Farah, Deepti Bhargava, Francis O'NEill, Bernhard Frank, et al.

    Introduction: This cross‐sectional study aims to assess somatosensory function in patients with trigeminal neuralgia (TN) using quantitative sensory testing (QST) and QST‐based sensory phenotyping, and to investigate their relationship with clinical findings, including etiology (classical and idiopathic TN), type of pain (paroxysmal pain only and concomitant continuous pain), and response to pharmacological treatment. Methods: Sixty‐five patients with classical or idiopathic TN underwent QST. Sensory alterations were quantified using z ‐scores derived from normative data, and sensory profiles were identified using a validated algorithm. Clinical characteristics, presence of concomitant continuous pain, and response to first‐line sodium channel blockers were systematically recorded through a structured questionnaire. Results: QST showed bilateral thermal hypoesthesia and pain hyperesthesia in the whole patient population. Cold detection threshold (CDT) was significantly reduced on the affected side compared to the unaffected side in patients with Classical TN. Idiopathic TN was associated with bilaterally elevated wind‐up ratio. Patients with purely paroxysmal pain showed a bilateral gain of function in heat pain thresholds. Sensory phenotyping identified mechanical hyperalgesia (49%) and thermal hyperalgesia (35%) as predominant phenotypes. A sensory loss phenotype was significantly associated with poor response to sodium‐channel blockers. Discussion: TN is characterized by subtle and complex bilateral sensory alterations, potentially suggesting central modification of sensory processing. The finding of asymmetrical CDT reduction may indicate peripheral Aδ‐fiber dysfunction. Sensory profiling may identify subgroups with distinctive treatment responses, with sodium channel blockers being less effective in sensory loss phenotype.


  • Open Access

    Trigeminal root dislocation subtends focal demyelination of primary trigeminal afferents in patients with trigeminal neuralgia

    by G De Stefano, D Litewczuk, C. Mollica, C. Leone, E. Galosi, G Di Pietro, P. Falco, N. Esposito, E. Evangelisti, D. Chiffi, et al.


  • Open Access

    Muscle Ultrasound in Inclusion Body Myositis: Integrating Qualitative and Quantitative Approaches With Clinical and MRI Findings

    by Giuseppe Di Pietro, Pietro Falco, Rocco Costanzo, Eleonora Galosi, Gianfranco De Stefano, Enrico Evangelisti, Antonio Lauletta, Caterina Leone, Daniel Litewczuk, Giulia Di Stefano, et al.

    Introduction/Aims: Inclusion body myositis (IBM) is an inflammatory myopathy with an insidious onset, often making diagnosis challenging. Although neuroimaging has recently been included in diagnostic criteria, the role of muscle ultrasound—despite being a rapid and cost‐effective tool—in IBM has been less extensively characterized. In this study, we aimed to explore whether qualitative and quantitative muscle ultrasound measures reflect the pattern of muscle involvement in IBM and are associated with magnetic resonance imaging (MRI) findings. Methods: Thirteen patients with histologically confirmed IBM underwent clinical evaluation, including the IBM Functional Rating Scale (IBM‐FRS) and Medical Research Council (MRC) grading. Qualitative (Heckmatt scale, from 1 to 4) and quantitative (muscle echo‐intensity and thickness z‐scores) ultrasound assessments were performed on fourteen muscles bilaterally. Lower limb muscle MRI was conducted using T1‐weighted (with Mercuri score) and STIR sequences. Correlations between ultrasound parameters and MRI findings were analyzed. Results: Qualitative ultrasound assessment showed increased echogenicity, mainly in flexor digitorum profundus, vastus lateralis, rectus femoris, tibialis anterior, and medial gastrocnemius. Quantitative analysis confirmed elevated echo‐intensity in these muscles, with milder involvement of tibialis anterior and lateral gastrocnemius. Both qualitative Heckmatt scores and quantitative muscle echo‐intensity scores showed positive associations with MRI T1 Mercuri scores ( p < 0.001). Discussion: In this study, both qualitative and quantitative muscle ultrasound reflected the characteristic pattern of muscle involvement in IBM and showed associations with MRI findings, supporting their utility in describing the pattern and extent of muscle damage.

  • Open Access

    Autonomic dysfunction in fibromyalgia syndrome: the role of small fiber damage

    by Pietro Falco, Caterina Maria Leone, Eleonora Galosi, Nicoletta Esposito, Gianfranco De Stefano, Giuseppe Di Pietro, Giulia Di Stefano, Enrico Evangelisti, Daniel Litewczuk, Claudia Urani, et al.


  • Open Access

    Diagnostic Potential of Combined Skin Morphometric Analysis and Salivary Alpha-Synuclein Oligomers in Parkinson’s Disease

    by Claudia Caturano, Francesco Emanuele Bellomi, Eleonora Galosi, Maria Ilenia De Bartolo, Matteo Costanzo, Francesca Arciprete, Maria Zingariello, Massimo Marano, Antonella Conte, Giovanni Fabbrini, et al.

    Oligomeric species of alpha-synuclein (α-syn) in saliva and phosphorylated α-syn deposits in the skin are established molecular biomarkers for Parkinson’s disease (PD). However, existing research has yet to fully explore the diagnostic potential of non-phosphorylated α-syn and other cutaneous morphometric parameters, such as variations in collagen type IV within the dermis and epidermis or α-syn expression in melanocytes. This study aims to evaluate and compare the diagnostic utility of these skin morphometric parameters in differentiating 32 PD patients from 19 healthy subjects (HSs), while also examining their correlation with salivary α-syn oligomer levels. Skin biopsies were analyzed via immunofluorescence and confocal microscopy, while salivary oligomeric α-syn was quantified through competitive ELISA. Results revealed a significant reduction in α-syn-positive fibres in PD patients compared to HSs (0.91; <0.0001). Conversely, the collagen staining area and the number of α-syn-positive melanocytes were significantly increased in the skin of PD patients. Specifically, the collagen type IV staining area was significantly higher in the dermis and surrounding the sweat glands of PD patients, demonstrating optimal diagnostic power (0.9448; <0.0001). Similarly, the increase in α-syn-positive melanocytes in PD patients showed robust diagnostic potential (0.84; <0.001). Salivary α-syn oligomers accurately discriminated between PD and HS groups. Furthermore, significant correlations were found between collagen type IV and melanocyte morphometric parameters and various clinical scores in PD. Our findings highlight how multimodal morphometric analysis of the skin can enhance diagnostic accuracy in PD, supporting the use of salivary and cutaneous biomarkers as complementary tools that may reflect distinct aspects of PD pathology.

  • Quantitative sensory testing–based sensory phenotypes align with measures of peripheral nerve damage in patients with painful polyneuropathies

    by Eleonora Galosi, Caterina Leone, Pietro Falco, Giuseppe Di Pietro, Gianfranco De Stefano, Nicoletta Esposito, Enrico Evangelisti, Daniel Litewczuk, Lorenzo Tramontana, Rocco Costanzo, et al.

    Quantitative sensory testing (QST) is increasingly used to stratify patients with peripheral neuropathic pain into sensory phenotypes that may reflect distinct underlying pain mechanisms. Yet, their correspondence with objective measures of peripheral nerve damage remains unclear. This study investigated whether QST-based phenotypes are associated with objective measures of peripheral nerve damage in patients with painful polyneuropathy. We retrospectively analyzed data from 130 patients with painful polyneuropathy, who underwent nerve conduction studies, distal leg skin biopsy, and QST at the foot dorsum. Using an established algorithm, patients were classified into 4 QST sensory phenotypes: Sensory Loss, Mechanical Hyperalgesia, Thermal Hyperalgesia, and Healthy. We assessed sural sensory nerve action potential (SNAP) amplitude, intraepidermal nerve fiber density using PGP9.5, TRPV1, and GAP43 immunostaining, as well as TRPV1 and GAP43/PGP9.5 ratios. These parameters were compared across QST phenotypes. Associations were analyzed using multinomial logistic regression models. Patients with the Sensory Loss phenotype—the most prevalent subgroup—had significantly lower sural SNAP amplitudes and intraepidermal nerve fiber densities of PGP9.5, TRPV1, and GAP43, compared with the other phenotypes. Compared with Sensory Loss, Mechanical Hyperalgesia demonstrated higher sural SNAP amplitudes ( P < 0.0001), TRPV1/PGP9.5 ( P = 0.018), and GAP43/PGP9.5 ratios ( P = 0.011), whereas Thermal Hyperalgesia was associated with higher sural SNAP amplitudes ( P = 0.041) and PGP9.5 intraepidermal nerve fiber density ( P = 0.025). Our study demonstrates that QST-based phenotypes are associated with distinctive patterns of peripheral nerve damage in patients with painful polyneuropathy. These findings suggest that QST phenotyping may capture different aspects of underlying pain mechanisms, supporting its value for mechanism-based patient stratification.


  • Open Access

    Comparative Analysis of Small Nerve Fiber Density in Fibromyalgia Syndrome and Small Fiber Neuropathy

    by Pietro Falco, Eleonora Galosi, Caterina Maria Leone, Gianfranco De Stefano, Giuseppe Di Pietro, Giulia Di Stefano, Nicoletta Esposito, Enrico Evangelisti, Daniel Litewczuk, Cristina Mollica, et al.

    Background/Objectives: Fibromyalgia syndrome is commonly associated with reduced intraepidermal nerve fiber density (IENFD), as assessed by skin biopsy, a finding referred to as small fiber pathology (SFP-FMG). The clinical significance of this abnormality, and how it relates to symptoms in fibromyalgia, remains uncertain. Reduced IENFD also represents the defining feature of small fiber neuropathy (SFN). While previous observations suggest that IENFD reduction is generally less severe in SFP-FMG than in SFN, no study has directly confirmed this finding in a large cohort. This retrospective study aimed to compare the severity of IENFD reduction in patients with SFP-FMG and those with SFN. Methods: To account for age and sex differences, we used the age-and sex-adjusted axonal loss density (ALD), defined as the percentage reduction from normative IENFD values. We retrospectively analyzed skin biopsy data from 73 patients with SFP-FMG and 134 patients diagnosed with SFN. Results: We found that the reduction in IENFD was significantly milder in patients with SFP-FMG than in those with SFN both at distal and proximal sites. Receiver operating characteristic analysis indicated that an ALD threshold of 37.6% provided good specificity for distinguishing SFN from SFP-FMG. Conclusions: These findings indicate that small fiber damage in fibromyalgia syndrome is quantitatively mild compared to patients with SFN. This may explain the absence of detectable sensory deficits on clinical examination and suggests a limited contribution of peripheral nerve damage to the pathophysiology of fibromyalgia syndrome.


  • Diagnostic accuracy of quantitative sensory testing for detecting small fiber impairment in polyneuropathy and diagnosing small fiber neuropathy

    by Eleonora Galosi, Daniel Litewczuk, Gianfranco De Stefano, Giuseppe Di Pietro, Giulia Di Stefano, Nicoletta Esposito, Enrico Evangelisti, Pietro Falco, Caterina Leone, Juliane Sachau, et al.

    This cross-sectional retrospective study evaluated the diagnostic accuracy of cold detection thresholds (CDT) and warm detection thresholds (WDT), measured by quantitative sensory testing, for detecting small fiber impairment in polyneuropathy and diagnosing small fiber neuropathy (SFN). A total of 384 individuals with distally distributed sensory disturbances were included. Using ACTTION criteria, 138 patients with polyneuropathy were identified. Among them, 36 were diagnosed with SFN, 91 with mixed fiber polyneuropathy, and 11 with pure large fiber polyneuropathy. First, we assessed CDT and WDT accuracy, both individually and combined (ie, an abnormal value in either CDT or WDT), in detecting small fiber impairment in polyneuropathy. Next, we calculated CDT and WDT diagnostic accuracy for SFN, both alone and combined, and evaluated their accuracy when integrated with small fiber–related clinical abnormalities. Isolated abnormalities in CDT or WDT showed relatively low diagnostic accuracy. However, combined abnormalities achieved a sensitivity of 69% and specificity of 70% for detecting small fiber impairment in distal symmetric polyneuropathy. For SFN diagnosis, combining CDT and WDT yielded 78% sensitivity, 70% specificity, and a 94% negative predictive value. These metrics improved to 78% sensitivity and 100% specificity when CDT or WDT were integrated with small-fiber-related clinical abnormalities. Although individual CDT and WDT assessments offer limited diagnostic accuracy, their combination provides a practical, noninvasive approach for screening small fiber impairment in distal symmetric polyneuropathy and diagnosing SFN. This strategy may reduce the need for more invasive and less cost-effective procedures, like skin biopsy.